David Proia

Company: Acrivon Therapeutics

Job title: Vice President, Biology and Drug Discovery

Seminars:

Predictive Precision Proteomics (AP3) Platform Uncovers Need for Dual WEE1/PKMYT1 Inhibition for Superior Single Agent Activity, Leading to the Discovery of ACR-2316 1:45 pm

Discussing Acrivon’s AP3-based finding that balanced PKMYT1 inhibition overcomes a dominant cellular WEE1 inhibition-induced resistance mechanism resulting in superior single agent activity Exploring how Acrivon leveraged its AP3 platform to identify the key signaling nodes associated with maximum on-target activity and guide drug candidate selection Analyzing the mechanism of action and potentially class leading potency…Read more

day: Day Two